Is Mankind Pharma (MANKIND) overvalued or fairly valued?

MarketChacha shows Mankind Pharma's valuation in context — a forward P/E of about 36.0, a price-to-book of about 6.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Mankind Pharma's revenue?

Mankind Pharma reported revenue of ₹14,278 Cr for FY2026, with net profit of ₹1,913 Cr, per official filings.

What is the share price of Mankind Pharma (MANKIND)?

Mankind Pharma last traded at ₹2,571.00 (+3.5% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Mankind Pharma

MANKIND · NSE · Pharma · India

₹2,571.00+3.5%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:40 AM

Snapshot

TickerMANKIND

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees20,451

HeadquartersNew Delhi, India

Market cap₹1,05,967 Cr

P/B6.5

Volume60.78K

Websitewww.mankindpharma.com

Filings tracked0

About Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters75.4%
Institutions20.0%
Public & other4.6%

175 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend14.7% → 13.4%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 18% · PAT 14%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹4,162 Cr · EPS 17.30

Next fiscal year

Rev ₹17,889 Cr · EPS 71.26

Est. earnings growth +24.6%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,909.7052-wk range₹2,694.90

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹1,05,967 Cr

Day change

+3.5%

Fwd P/E

36.0

P/B

6.5

Div yield

0.08%

Beta

0.45

Revenue (FY2026)

₹14,278 Cr

Net margin

13.4%

Revenue CAGR (3y)

+17.7%

Profit CAGR (3y)

+14.3%

Net profit (FY2026)

₹1,913 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about MANKIND

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹14,278 Cr	₹1,913 Cr	13.4%
FY2025	₹12,207 Cr	₹1,991 Cr	16.3%
FY2024	₹10,335 Cr	₹1,913 Cr	18.5%
FY2023	₹8,749 Cr	₹1,282 Cr	14.7%

Quarterly

Period	Revenue	Net profit	Net margin
2026Q1	₹3,443 Cr	₹554 Cr	16.1%
2025Q4	₹3,567 Cr	₹409 Cr	11.5%
2025Q3	₹3,697 Cr	₹512 Cr	13.8%
2025Q2	₹3,570 Cr	₹438 Cr	12.3%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.